Related Experiment Video
Updated: Jul 18, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
[Stroke in Fabry disease. More than a simple stenosis]
1Servicio de Neurología, Hospital Juan A. Fernández, Buenos Aires, Argentina. jpolitei@hotmail.com
Insights
Fabry disease, caused by alpha-galactosidase A deficiency, leads to cerebrovascular damage through lipid accumulation. Enzyme replacement therapy shows promise in reversing these pathological mechanisms.
Area of Science:
- Biochemistry
- Neurology
- Genetics
Context:
- Fabry disease is a rare genetic disorder.
- It results from alpha-galactosidase A deficiency.
- This deficiency causes glycosphingolipid accumulation.
Purpose:
- To review updated evidence on physiopathological mechanisms of cerebrovascular damage in Fabry disease.
- To explore the impact of enzyme replacement therapy on these mechanisms.
Summary:
- Cerebrovascular complications, including stroke, are a major cause of mortality in Fabry disease.
- Historically, lipid deposition in endothelial cells was the primary suspected mechanism.
- Emerging evidence suggests additional physiopathological pathways contribute to cerebrovascular damage.
Impact:
- Enzyme replacement therapy offers potential for reversing disease mechanisms.
- Further long-term studies are needed to confirm treatment efficacy.
- Understanding these mechanisms is crucial for developing targeted therapies.
Abstract:
The objective is to analyze the updated evidence on the physiopathological mechanisms that can generate cerebrovascular damage in Fabry disease. Fabry disease is the result of the deficiency of alpha-galactosidasa A, which causes pathological storage of glycosphingolipids, in different cells. Associated to renal and cardiac insufficiency, cerebrovascular complications can derive in the death of the patients. During a long time the only reported mechanism was the vascular occlusion by deposit of lipids at endothelial level. At the present time, other mechanisms are postulated. The arrival of enzyme replacement therapy has generated great expectation on the possibility of reversion of these alterations. Although the evidence is scarce and more long-term studies are necessary, some reports demonstrate that after months, the treatment has managed to revert some of the mechanisms involved.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Mitral Stenosis I: Introduction
Ischemic Stroke l: Introduction
Rheumatic Heart Disease I: Introduction
Ischemic Stroke ll: Pathophysiology
Stroke: Introduction and Types

